$CVAT
Cavitation Technologies, Inc.

2024 Q4 Form 10-Q Financial Statement

#000168316824008046 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $8.000K
YoY Change -77.78%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $8.000K
YoY Change -96.8%
Operating Profit -$226.0K
YoY Change -9.6%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$227.0K
YoY Change -9.56%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 284.3M shares 284.3M shares
Diluted Shares Outstanding 284.3M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.000K
YoY Change -98.57%
Cash & Equivalents $2.000K
Short-Term Investments
Other Short-Term Assets $40.00K
YoY Change
Inventory
Prepaid Expenses $40.00K
Receivables
Other Receivables
Total Short-Term Assets $42.00K
YoY Change -70.0%
LONG-TERM ASSETS
Property, Plant & Equipment $24.00K
YoY Change 2300.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.000K
YoY Change 0.0%
Other Assets $10.00K
YoY Change 0.0%
Total Long-Term Assets $35.00K
YoY Change -67.29%
TOTAL ASSETS
Total Short-Term Assets $42.00K
Total Long-Term Assets $35.00K
Total Assets $77.00K
YoY Change -68.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $187.0K
YoY Change 29.86%
Accrued Expenses $460.0K
YoY Change 16.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $9.000K
YoY Change 80.0%
Total Short-Term Liabilities $656.0K
YoY Change -47.01%
LONG-TERM LIABILITIES
Long-Term Debt $128.0K
YoY Change -11.72%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $128.0K
YoY Change -28.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $656.0K
Total Long-Term Liabilities $128.0K
Total Liabilities $784.0K
YoY Change -44.67%
SHAREHOLDERS EQUITY
Retained Earnings -$27.07M
YoY Change -1.68%
Common Stock $284.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$707.0K
YoY Change
Total Liabilities & Shareholders Equity $77.00K
YoY Change -68.83%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$227.0K
YoY Change -9.56%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$175.0K
YoY Change -243.44%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$2.000K
YoY Change
NET CHANGE
Cash From Operating Activities -$175.0K
Cash From Investing Activities
Cash From Financing Activities -$2.000K
Net Change In Cash -$177.0K
YoY Change -245.08%
FREE CASH FLOW
Cash From Operating Activities -$175.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001376793
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity File Number
EntityFileNumber
000-53239
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4907818
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
10019 CANOGA AVENUE
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
CHATSWORTH
CY2024Q3 dei City Area Code
CityAreaCode
818
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179000 usd
CY2024Q3 dei Amendment Flag
AmendmentFlag
false
CY2024Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
718-0905
CY2024Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
Cavitation Technologies, Inc.
CY2024Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91311
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
284289740 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
40000 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
42000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
195000 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
1000 usd
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
1000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42000 usd
CY2024Q3 us-gaap Other Assets
OtherAssets
10000 usd
CY2024Q2 us-gaap Other Assets
OtherAssets
10000 usd
CY2024Q3 us-gaap Assets
Assets
77000 usd
CY2024Q2 us-gaap Assets
Assets
248000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
187000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
129000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
433000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
414000 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
9000 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
9000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
27000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
46000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
656000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
598000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
128000 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
130000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
784000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
728000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
284289740 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
284289740 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
284289740 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
284289740 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
284000 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
284000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26083000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26083000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27074000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26847000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-707000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-480000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
248000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
218000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
214000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-226000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-250000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-227000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-251000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
284289740 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
284289740 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
284289740 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
284289740 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-480000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-227000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-707000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-919000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-251000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1170000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-227000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-251000 usd
CY2024Q3 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
24000 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-0 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
18000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
18000 usd
CY2024Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
58000 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
24000 usd
CY2024Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
19000 usd
CY2023Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
46000 usd
CY2024Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
CY2023Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
304000 usd
CY2024Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-19000 usd
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-19000 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-175000 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
122000 usd
CY2024Q3 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2000 usd
CY2023Q3 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-0 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2000 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-177000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
122000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140000 usd
CY2024Q3 us-gaap Interest Paid Net
InterestPaidNet
1000 usd
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
2000 usd
CY2024Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-227000 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-175000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-707000 usd
CY2024Q3 CVAT Working Capital
WorkingCapital
-614000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27074000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2000 usd
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zn9WbsGljGSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_864_z4IXFNldObx8">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include estimates for reserves for valuation of our equity method investments, assumptions used in valuing our stock options, stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
1000 usd
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
1000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36000 usd
CY2024Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zbqadvju0Sw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_860_zKZqt5ap7QLg">Concentrations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30, 2024 and 2023, we recorded <span id="xdx_908_eus-gaap--Revenues_do_c20240701__20240930_zhmOVfSqcCY9" title="Revenue"><span id="xdx_904_eus-gaap--Revenues_do_c20230701__20230930_zd54K9fvnEf5" title="Revenue">no</span></span> revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, three vendors accounted <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zDPGfQtYcxF" title="Concentration risk, percentage">27</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zdcELv6LEfDl" title="Concentration risk, percentage">20</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_zYq05AIoLOub" title="Concentration risk, percentage">9</span>% of the Company’s accounts payable. As of June 30, 2024, three vendors accounted <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zMdTVs1dLnu6" title="Concentration risk, percentage">19</span>%, <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zo85zOKGHsRh" title="Concentration risk, percentage">15</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_zPWe7w1n6bF7" title="Concentration risk, percentage">11</span>% of the Company’s accounts payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2024 and June 30, 2024, we had <span id="xdx_909_eus-gaap--AccountsReceivableNet_iI_pp0p0_do_c20240930_zQ4zav3N1JSi" title="Receivables from customers"><span id="xdx_900_eus-gaap--AccountsReceivableNet_iI_pp0p0_do_c20240630_zJHkTAGhWWM5" title="Receivables from customers">no</span></span> receivables from our customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2024Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2024Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2023 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
1112000 usd
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1000 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
1000 usd
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
1000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
19000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
19000 usd
CY2024Q3 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
21000 usd
CY2023Q3 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
17000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.04 pure
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.04 pure
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
95000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
27000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
68000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
27000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
102000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
27000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
-0 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
27000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
280000 usd
CY2024Q2 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
134000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
414000 usd
CY2024Q3 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
12000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
426000 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
137000 usd
CY2024Q2 us-gaap Notes Payable
NotesPayable
139000 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
9000 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
9000 usd
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
128000 usd
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
130000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-008046-index-headers.html Edgar Link pending
0001683168-24-008046-index.html Edgar Link pending
0001683168-24-008046.txt Edgar Link pending
0001683168-24-008046-xbrl.zip Edgar Link pending
cavitationlogo.jpg Edgar Link pending
cavitation_ex3101.htm Edgar Link pending
cavitation_ex3102.htm Edgar Link pending
cavitation_ex3201.htm Edgar Link pending
cavitation_ex3202.htm Edgar Link pending
cavitation_i10q-093024.htm Edgar Link pending
cvat-20240930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
cvat-20240930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cavitation_i10q-093024_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cvat-20240930_cal.xml Edgar Link unprocessable
cvat-20240930_pre.xml Edgar Link unprocessable
cvat-20240930_lab.xml Edgar Link unprocessable